Evidence map›Paper›PMID 42033784›Full record

ArticleRheumatology (Oxford, England)2026

Clinical outcomes in psoriatic arthritis patients with rheumatoid factor positivity.

Pankti Mehta, Fadi Kharouf, Virginia Carrizo Abarza, Shangyi Gao, Dafna D Gladman, Vinod Chandran, Denis Poddubnyy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Pankti MehtaGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0001-9134-0999
Fadi KharoufGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0002-3540-0341
Virginia Carrizo AbarzaGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.
Shangyi GaoGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.
Dafna D GladmanGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0002-9074-0592
Vinod ChandranGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.
Denis PoddubnyyGladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe clinical and immunologic significance of rheumatoid factors (RF) in psoriatic arthritis (PsA) remains unclear. We aimed to determine the frequency and impact of RF positivity on clinical outcomes and biologic (b) disease-modifying anti-rheumatic drug (DMARD) discontinuation in PsA.

methodsPatients enrolled after 1996 from a large PsA cohort were included for this study. RF was tested annually and was defined as ever positive or newly positive (excluding those positive at enrolment). Associations of RF with clinical outcomes, including achievement of minimal disease activity (MDA), components of MDA and bDMARD discontinuation, were assessed using univariable (UV) and multivariable (MV) generalized estimating equations.

resultsAmong 1074 patients, RF positivity was observed in 173 (16.1%) overall, including 55 (5.1%) who were positive at baseline. RF positivity was significantly associated with reduced odds for achievement of MDA (MV, OR 0.53, 95% CI 0.37-0.77), driven by worse patient pain, patient global and physical function, particularly in the bDMARD subgroup. These associations persisted in the bDMARDs subgroup when analyses were restricted to new RF positivity. Additionally, ever and new RF positivity was associated with increased odds for bDMARD discontinuation (MV, OR 2.65, 95% CI 1.34-5.24 and 2.78, 95% CI 1.57-4.92, respectively) independent of joint and skin disease activity.

conclusionRF was observed in 16.1% of the cohort, with 5.1% being positive at baseline. RF positivity was associated with lower odds for achievement of MDA and with bDMARD discontinuation.

Indexed as

Antirheumatic AgentsArthritis, PsoriaticBiological ProductsRheumatoid FactorAdultFemaleHumansMaleMiddle AgedSeverity of Illness IndexTreatment OutcomeAntirheumatic AgentsBiological ProductsRheumatoid Factorantirheumatic agentsbiological productspainpsoriatic arthritisrheumatoid factor

Identifiers

PMID42033784
PMCPMC13215877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.